<DOC>
	<DOC>NCT02942602</DOC>
	<brief_summary>1) to test HDL function comprehensively in healthy and diseased individuals; 2) to evaluate if this test correlates with cardiovascular risk, independent of traditional risk factors; 3) and to differentiate effects of lipid-modifying or antiatherosclerotic drugs on HDL function and composition</brief_summary>
	<brief_title>Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Cholestyramine Resin</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipidlowering therapy Aged over 20 Consent form signed pregnant or lactating women subjects with familial hypercholesterolemia uncontrolled hypertension or DM Thyroid dysfunction Active liver disease (transaminase or bilirubin &gt; 1.5 x NL) Serum creatinine &gt; 2 mg/dL Included in other clinical trials within 3 months using of other medication: fish oil, fibric acid derivatives, niacin, systemic corticosteroid, thiazolidinedione</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>